UA108888C2 - Кристал аміду - Google Patents

Кристал аміду

Info

Publication number
UA108888C2
UA108888C2 UAA201300523A UAA201300523A UA108888C2 UA 108888 C2 UA108888 C2 UA 108888C2 UA A201300523 A UAA201300523 A UA A201300523A UA A201300523 A UAA201300523 A UA A201300523A UA 108888 C2 UA108888 C2 UA 108888C2
Authority
UA
Ukraine
Prior art keywords
ylcarbonyl
methoxybutyl
morpholin
methylpropyl
piperidin
Prior art date
Application number
UAA201300523A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of UA108888C2 publication Critical patent/UA108888C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UAA201300523A 2010-06-16 2011-06-15 Кристал аміду UA108888C2 (xx)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010137194 2010-06-16
PCT/JP2011/063735 WO2011158880A1 (ja) 2010-06-16 2011-06-15 アミド化合物の結晶

Publications (1)

Publication Number Publication Date
UA108888C2 true UA108888C2 (xx) 2015-06-25

Family

ID=45348277

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201300523A UA108888C2 (xx) 2010-06-16 2011-06-15 Кристал аміду

Country Status (27)

Country Link
US (1) US9018374B2 (ru)
EP (1) EP2583967B1 (ru)
JP (1) JP5782438B2 (ru)
KR (1) KR20130119903A (ru)
CN (1) CN103068816B (ru)
AU (1) AU2011266099B2 (ru)
BR (1) BR112012032055B8 (ru)
CA (1) CA2802483C (ru)
CL (1) CL2012003526A1 (ru)
CO (1) CO6670573A2 (ru)
DO (1) DOP2012000313A (ru)
EA (1) EA022094B1 (ru)
EC (1) ECSP13012392A (ru)
ES (1) ES2524896T3 (ru)
GE (1) GEP20146195B (ru)
HK (1) HK1179605A1 (ru)
IL (1) IL223562A (ru)
MA (1) MA34378B1 (ru)
MX (1) MX2012014828A (ru)
MY (1) MY163927A (ru)
PE (1) PE20130283A1 (ru)
SG (1) SG186223A1 (ru)
TN (1) TN2012000589A1 (ru)
TW (1) TWI511967B (ru)
UA (1) UA108888C2 (ru)
WO (1) WO2011158880A1 (ru)
ZA (1) ZA201300065B (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107879941A (zh) * 2012-02-14 2018-04-06 陶氏环球技术有限责任公司 非离子型表面活性剂组合物
EP2814466B1 (en) * 2012-02-15 2018-12-26 Takeda Pharmaceutical Company Limited Tablet comprising 1-(4-methoxybutyl)-n-(2-methylpropyl)-n-[(3s,5r)-5-(morpholin-4-ylcarbonyl)piperidin-3-yl]-1h-benzimidazole-2-carboxamide or a salt thereof
CN103831159B (zh) * 2014-01-20 2016-04-13 华润赛科药业有限责任公司 一种阿齐沙坦微粉化方法
EP3130581A4 (en) * 2014-04-10 2017-11-22 Takeda Pharmaceutical Company Limited Method for producing heterocyclic compound
GB2542876B (en) * 2015-04-20 2019-10-23 Johnson Matthey Plc Structure Directing Agent
CN107595853A (zh) * 2017-10-25 2018-01-19 桂林浩新科技服务有限公司 一种用于治疗高血压合并冠心病的药物组合物及其用途
CN107595842A (zh) * 2017-10-25 2018-01-19 桂林浩新科技服务有限公司 一种药物复方制剂及在制备治疗高血压合并冠心病的药物中的用途

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6944296A (en) 1995-09-13 1997-04-01 Takeda Chemical Industries Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
EP1302462A4 (en) 2000-07-17 2007-07-18 Takeda Pharmaceutical Sulphonic derivatives, process for their preparation and their use
US7342117B2 (en) * 2001-10-30 2008-03-11 Astellas Pharma Inc. α-form or β-form crystal of acetanilide derivative
PE20040609A1 (es) 2002-11-01 2004-10-29 Takeda Pharmaceutical Compuestos heterociclicos aromaticos como promotores de un factor neurotrofico
US7960369B2 (en) 2002-11-08 2011-06-14 Takeda Pharmaceutical Company Limited Receptor function regulator
WO2004048363A1 (ja) 2002-11-22 2004-06-10 Takeda Pharmaceutical Company Limited イミダゾール誘導体、その製造法および用途
JP3618341B2 (ja) * 2003-04-15 2005-02-09 山之内製薬株式会社 臭化物及びその結晶
US20060223831A1 (en) 2003-04-15 2006-10-05 Isao Kinoyama Bromide and its crystal
CA2527691C (en) 2003-05-30 2013-01-22 Takeda Pharmaceutical Company Limited Condensed ring compound
AU2004247615B2 (en) 2003-06-18 2008-02-21 Astrazeneca Ab 2-substituted 5,6-diaryl-pyrazine derivatives as CB1 modulators
WO2005030740A1 (ja) 2003-09-30 2005-04-07 Takeda Pharmaceutical Company Limited チアゾリン誘導体およびその用途
JP4769082B2 (ja) 2003-12-17 2011-09-07 武田薬品工業株式会社 ウレア誘導体、その製造法及び用途
RU2006126978A (ru) 2003-12-25 2008-01-27 Такеда Фармасьютикал Компани Лимитед (Jp) Производные 3-(4-бензилоксифенил)пропановой кислоты
JP4855777B2 (ja) 2003-12-26 2012-01-18 武田薬品工業株式会社 フェニルプロパン酸誘導体
WO2005087710A1 (ja) 2004-03-15 2005-09-22 Takeda Pharmaceutical Company Limited アミノフェニルプロパン酸誘導体
WO2005095338A1 (ja) 2004-03-30 2005-10-13 Takeda Pharmaceutical Company Limited アルコキシフェニルプロパン酸誘導体
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
JP5094394B2 (ja) 2005-04-20 2012-12-12 武田薬品工業株式会社 縮合複素環化合物
US20090208584A1 (en) 2005-06-09 2009-08-20 Tomohiro Yoshinari Solid preparation
GB0514203D0 (en) 2005-07-11 2005-08-17 Novartis Ag Organic compounds
WO2007013694A1 (ja) 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited フェノキシアルカン酸化合物
WO2007013689A1 (ja) 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited シクロプロパンカルボン酸化合物
CN101282725A (zh) 2005-08-10 2008-10-08 武田药品工业株式会社 糖尿病治疗剂
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
RS52307B (en) 2006-06-27 2012-12-31 Takeda Pharmaceutical Company Limited CONDENSED CYCLIC UNITS
JP5306818B2 (ja) 2006-10-18 2013-10-02 武田薬品工業株式会社 縮合複素環化合物
US7652133B2 (en) 2006-10-19 2010-01-26 Takeda Pharmaceutical Company Limited Indole compound
US20100016396A1 (en) 2007-01-29 2010-01-21 Hiroshi Imoto Pyrazole compound
AU2008215490A1 (en) 2007-02-09 2008-08-21 Takeda Pharmaceutical Company Limited Fused ring compounds as partial agonists of PPAR-gamma
WO2008136428A1 (ja) 2007-04-27 2008-11-13 Takeda Pharmaceutical Company Limited 含窒素5員複素環化合物
US20110301155A1 (en) 2007-06-19 2011-12-08 Tsuneo Yasuma Indazole compounds for activating glucokinase
JP2010229034A (ja) 2007-07-26 2010-10-14 Dainippon Sumitomo Pharma Co Ltd 二環性ピロール誘導体
PT2297114T (pt) 2008-06-19 2018-07-26 Takeda Pharmaceuticals Co Composto heterocíclico e a sua utilização
JP4901849B2 (ja) 2008-12-15 2012-03-21 バブコック日立株式会社 空気清浄機、及び分析室、並びに空気の浄化方法
US8642622B2 (en) 2010-06-16 2014-02-04 Bristol-Myers Squibb Company Piperidinyl compound as a modulator of chemokine receptor activity

Also Published As

Publication number Publication date
ZA201300065B (en) 2014-03-26
SG186223A1 (en) 2013-01-30
CN103068816B (zh) 2015-01-07
EP2583967A1 (en) 2013-04-24
CO6670573A2 (es) 2013-05-15
KR20130119903A (ko) 2013-11-01
CA2802483C (en) 2017-10-24
TW201206914A (en) 2012-02-16
BR112012032055B8 (pt) 2019-11-12
EP2583967B1 (en) 2014-10-01
EP2583967A4 (en) 2013-09-04
CL2012003526A1 (es) 2013-05-31
ES2524896T3 (es) 2014-12-15
CN103068816A (zh) 2013-04-24
GEP20146195B (en) 2014-11-10
CA2802483A1 (en) 2011-12-22
ECSP13012392A (es) 2013-03-28
US20130090337A1 (en) 2013-04-11
EA022094B1 (ru) 2015-10-30
MY163927A (en) 2017-11-15
WO2011158880A1 (ja) 2011-12-22
BR112012032055B1 (pt) 2019-10-22
PE20130283A1 (es) 2013-03-25
BR112012032055A2 (pt) 2016-11-08
JPWO2011158880A1 (ja) 2013-08-19
HK1179605A1 (en) 2013-10-04
US20130252954A2 (en) 2013-09-26
EA201291453A1 (ru) 2013-05-30
MA34378B1 (fr) 2013-07-03
IL223562A (en) 2015-03-31
DOP2012000313A (es) 2013-02-15
JP5782438B2 (ja) 2015-09-24
MX2012014828A (es) 2013-02-27
AU2011266099A1 (en) 2013-01-24
AU2011266099B2 (en) 2014-09-11
TWI511967B (zh) 2015-12-11
US9018374B2 (en) 2015-04-28
TN2012000589A1 (en) 2014-04-01

Similar Documents

Publication Publication Date Title
UA108888C2 (xx) Кристал аміду
MY160771A (en) Heterocyclic compound and use thereof
RS51954B (en) CRYSTAL MODIFICATIONS OF PYRACLOSTROBIN
WO2009036175A3 (en) F1f0-atpase inhibitors and related methods
WO2007058602A3 (en) Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer’s disease, neurodegeneration and dementia.
GT201300165A (es) Compuestos y su uso como inhibidores de bace
WO2011150156A3 (en) Heteroaryl compounds and methods of use thereof
WO2008011130A8 (en) Amide compounds
WO2007058583A3 (en) Novel 2-amino-heterocycles useful in the treatment of abeta-related pathologies
WO2008011131A3 (en) Amide compounds
ZA200707531B (en) N-(N-Sulfonylaminomethyl) cyclopropanecarboxamide derivatives useful for the treatment of pain
ZA200907137B (en) Novel N-(8-heteroaryltetrahydronaphtalene-2yl) or N-(5-heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain
UY30312A1 (es) Derivados de n-(2-tiazolil)-amida como inhibidores de gsk-3
IN2012DN05028A (ru)
WO2010033701A3 (en) Inhibitors of sphingosine kinase 1
PT1828151E (pt) Derivados de malonamida como inibidores de gama-secretase para o tratamento da doença de alzheimer
JP2014526498A5 (ru)
WO2008149353A3 (en) Telomerase activating compounds and methods of use thereof
JP2009519974A5 (ru)
WO2009156041A3 (de) Thiazolyl-piperidinderivate
NZ598750A (en) Therapeutic agent for mood disorders
WO2009120192A3 (en) Processes for the preparation of benzo-fused dioxin derivatives
NO20080265L (no) 2-(1H-indolylsulfanyl)-arylaminderivater
WO2009158646A8 (en) Therapeutic compounds and related methods of use
WO2007149891A3 (en) Crystalline forms of gemcitabine amide prodrug, compositions and use thereof